Advertisement

Topics

Champions Oncology Enters Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of PDX Models

09:37 EDT 21 Aug 2017 | Speciality Pharma Journal

HACKENSACK, N.J., Aug. 21, 2017 /PRNewswire/ — Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in …

Original Article: Champions Oncology Enters Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of PDX Models

NEXT ARTICLE

More From BioPortfolio on "Champions Oncology Enters Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of PDX Models"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...